Application of Newcastle Disease Virus in the Treatment of Human and Canine Mammary Cancer

被引:1
作者
Coleto, Arlinda Flores [1 ]
Fonseca, Belchiolina Beatriz [2 ]
Medeiros-Ronchi, Alessandra Aparecida [1 ]
机构
[1] Univ Fed Uberlandia, Fac Vet Med, Lab Vet Pathol, Mato Grosso Ave,3289-Bloco 2S, Umuarama, MG, Brazil
[2] Univ Fed Uberlandia, Postgrad Program Genet & Biochem, Umuarama, MG, Brazil
关键词
Mammary; Neoplasm; Newcastle disease virus; Oncology; HEMAGGLUTININ-NEURAMINIDASE; ONCOLYTIC VIRUS; AF2240; STRAIN; CELLS; COMBINATION; APOPTOSIS; PATHWAYS; PATIENT; IMMUNE; TRIAL;
D O I
10.29261/pakvetj/2024.241
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Breast cancer is the most prevalent form of tumor worldwide and the leading cause of cancer among women globally. Similarly, mammary tumors are also common in canines, with a majority of them unfortunately being malignant. While chemotherapy is one of the most frequently employed treatments, it often comes with significant side effects. Consequently, alternative therapies are under investigation, including oncolytic viruses. The Newcastle disease virus (NDV) stands out due to its capacity to selectively target and destroy tumor cells while preserving healthy tissue, as well as its ability to trigger a robust antitumor immune response. Numerous studies support the utilization of NDV in treating various cancer types, ranging from brain tumors to gastrointestinal tract neoplasms. Other researches have also yielded promising results in the treatment of mammary neoplasms. This review aims to compile information about NDV and its application in oncolytic virotherapy for the study and treatment of human breast cancer and canine mammary tumors, employing cell lines, animal models, and clinical trials.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 76 条
  • [11] Animal models and therapeutic molecular targets of cancer: utility and limitations
    Cekanova, Maria
    Rathore, Kusum
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1911 - 1922
  • [12] MOLECULAR-CLONING OF COMPLEMENTARY-DNA TO NEWCASTLE-DISEASE VIRUS, AND NUCLEOTIDE-SEQUENCE ANALYSIS OF THE JUNCTION BETWEEN THE GENES ENCODING THE HEMAGGLUTININ NEURAMINIDASE AND THE LARGE PROTEIN
    CHAMBERS, P
    MILLAR, NS
    BINGHAM, RW
    EMMERSON, PT
    [J]. JOURNAL OF GENERAL VIROLOGY, 1986, 67 : 475 - 486
  • [13] Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models
    Cuadrado-Castano, Sara
    Ayllon, Juan
    Mansour, Mena
    de la Iglesia-Vicente, Janis
    Jordan, Stefan
    Tripathi, Shashank
    Garcia-Sastre, Adolfo
    Villar, Enrique
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (05) : 1247 - 1258
  • [14] Das A, 2017, Int J Chemical Studies, V5, P605
  • [15] Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus)
    Dimitrov, Kiril M.
    Ramey, Andrew M.
    Qiu, Xueting
    Bahl, Justin
    Afonso, Claudio L.
    [J]. INFECTION GENETICS AND EVOLUTION, 2016, 39 : 22 - 34
  • [16] Virulence of Newcastle disease virus: what is known so far?
    Dortmans, Jos C. F. M.
    Koch, Guus
    Rottier, Peter J. M.
    Peeters, Ben P. H.
    [J]. VETERINARY RESEARCH, 2011, 42
  • [17] Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
    Elankumaran, Subbiah
    Rockemann, Daniel
    Samal, Siba K.
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (15) : 7522 - 7534
  • [18] Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
    Elankumaran, Subbiah
    Chavan, Vrushali
    Qiao, Dan
    Shobana, Raghunath
    Moorkanat, Gopakumar
    Biswas, Moanaro
    Samal, Siba K.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (08) : 3835 - 3844
  • [19] Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
    Freeman, AI
    Zakay-Rones, Z
    Gomori, JM
    Linetsky, E
    Rasooly, L
    Greenbaum, E
    Rozenman-Yair, S
    Panet, A
    Libson, E
    Irving, CS
    Galun, E
    Siegal, T
    [J]. MOLECULAR THERAPY, 2006, 13 (01) : 221 - 228
  • [20] Dose-related effects of smallpox vaccine
    Frey, SE
    Newman, FK
    Cruz, J
    Shelton, WB
    Tennant, JM
    Polach, T
    Rothman, AL
    Kennedy, JS
    Wolff, M
    Belshe, RB
    Ennis, FA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (17) : 1275 - 1280